BRPI1013538A2 - azetidinil diamidas como inibidores de monoacilglicerol lipase - Google Patents

azetidinil diamidas como inibidores de monoacilglicerol lipase

Info

Publication number: BRPI1013538A2
Authority: BR; Brazil
Prior art keywords: lipase inhibitors; monoacylglycerol lipase; diamides; azetidinyl; azetidinyl diamides
Prior art date: 2009-04-22

Application number

BRPI1013538A

Other languages

English (en)

Inventor

Zhu Bin

M Flores Christopher

Bian Haiyan

Mabus John

Clemente Jose

M Chevalier Kristen

Liu Li

E Mcdonnell Mark

J Macielag Mark

J Connolly Peter

M Pitis Philip

Lin Shu-Chen

Zhang Sui-Po

Zhang Yue-Mei

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-22

Filing date

2010-04-22

Publication date

2019-09-24

2010-04-22 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2019-09-24 Publication of BRPI1013538A2 publication Critical patent/BRPI1013538A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BRPI1013538A 2009-04-22 2010-04-22 azetidinil diamidas como inibidores de monoacilglicerol lipase BRPI1013538A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US17165809P	2009-04-22	2009-04-22
US17164909P	2009-04-22	2009-04-22
PCT/US2010/032068 WO2010124102A1 (en)	2009-04-22	2010-04-22	Azetidinyl diamides as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number	Publication Date
BRPI1013538A2 true BRPI1013538A2 (pt)	2019-09-24

Family

ID=42208680

Family Applications (8)

Application Number	Title	Priority Date	Filing Date
BRPI1013545A BRPI1013545A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1014284A BRPI1014284A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014885A BRPI1014885A8 (pt)	2009-04-22	2010-04-22	"azetidinil diamidas como inibidores de monoacilglicerol lipase."
BRPI1014281A BRPI1014281A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1013540-5A BRPI1013540A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipases
BRPI1013538A BRPI1013538A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1015238A BRPI1015238A2 (pt)	2009-04-22	2010-04-22	diamidas de azetidilina como inibidores de monoaciglicerol lipase
BRPI1014876A BRPI1014876A2 (pt)	2009-04-22	2010-04-22	"diamidas de azetidinila como inibidores de monoacilglicerol lipase."

Family Applications Before (5)

Application Number	Title	Priority Date	Filing Date
BRPI1013545A BRPI1013545A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipase
BRPI1014284A BRPI1014284A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1014885A BRPI1014885A8 (pt)	2009-04-22	2010-04-22	"azetidinil diamidas como inibidores de monoacilglicerol lipase."
BRPI1014281A BRPI1014281A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores da monoacilglicerol lipase
BRPI1013540-5A BRPI1013540A2 (pt)	2009-04-22	2010-04-22	azetidinil diamidas como inibidores de monoacilglicerol lipases

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
BRPI1015238A BRPI1015238A2 (pt)	2009-04-22	2010-04-22	diamidas de azetidilina como inibidores de monoaciglicerol lipase
BRPI1014876A BRPI1014876A2 (pt)	2009-04-22	2010-04-22	"diamidas de azetidinila como inibidores de monoacilglicerol lipase."

Country Status (21)

Country	Link
US (16)	US8426401B2 (pt)
EP (8)	EP2421825B9 (pt)
JP (8)	JP2012524800A (pt)
KR (8)	KR20120034615A (pt)
CN (8)	CN102803210A (pt)
AR (8)	AR076380A1 (pt)
AU (9)	AU2010239188B2 (pt)
BR (8)	BRPI1013545A2 (pt)
CA (8)	CA2759713A1 (pt)
DK (1)	DK2421825T3 (pt)
ES (2)	ES2455744T3 (pt)
HR (1)	HRP20140295T1 (pt)
IL (8)	IL215787A0 (pt)
PL (1)	PL2421825T3 (pt)
PT (1)	PT2421825E (pt)
RS (1)	RS53235B (pt)
RU (8)	RU2011147200A (pt)
SI (1)	SI2421825T1 (pt)
SM (1)	SMT201400034B (pt)
TW (8)	TW201105665A (pt)
WO (8)	WO2010124114A1 (pt)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010011493A1 (en)	2008-07-21	2010-01-28	Novartis Ag	Silicone-containing polymeric materals with hydrolyzable groups
BRPI1013545A2 (pt) *	2009-04-22	2019-09-24	Janssen Phamaceutica N V	azetidinil diamidas como inibidores de monoacilglicerol lipase
US9082128B2 (en) *	2009-10-19	2015-07-14	Uniloc Luxembourg S.A.	System and method for tracking and scoring user activities
WO2011058766A1 (en) *	2009-11-16	2011-05-19	Raqualia Pharma Inc.	Aryl carboxamide derivatives as ttx-s blockers
EP3002008B8 (en)	2010-03-11	2018-10-24	New York University	Amido compounds as roryt modulators and uses thereof
RU2013114771A (ru)	2010-09-03	2014-10-10	Янссен Фармацевтика Нв	Диамиды азетидинила как ингибиторы моноацилглицерол липазы
EP2621918A1 (en)	2010-09-27	2013-08-07	Janssen Pharmaceutica, N.V.	Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
CN102417483A (zh) *	2010-09-27	2012-04-18	中国药科大学	作为parp抑制剂的2-苯基-1h-苯并咪唑-4-甲酸酯衍生物
WO2012054716A1 (en) *	2010-10-22	2012-04-26	Janssen Pharmaceutica Nv.	Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
JP2013540160A (ja)	2010-10-22	2013-10-31	ヤンセンファーマシューティカエヌ．ベー．	モノアシルグリセロールリパーゼ阻害剤としてのアミノ−ピロリジン−アゼチジンジアミド
US8513423B2 (en)	2010-10-22	2013-08-20	Janssen Pharmaceutica, Nv	Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
CN103384661B (zh)	2011-01-20	2016-08-10	默沙东公司	盐皮质激素受体拮抗剂
US9388164B2 (en)	2011-05-03	2016-07-12	Agios Pharmaceuticals, Inc	Methods of using pyruvate kinase activators
KR20140068241A (ko) *	2011-09-30	2014-06-05	얀센 파마슈티카 엔.브이.	대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
CN104271573A (zh) *	2011-09-30	2015-01-07	詹森药业有限公司	(1-(4-氟苯基)-1h-吲哚-5-基)-(3-(4-(噻唑-2-羰基)哌嗪-1-基)氮杂环丁-1-基)甲酮的结晶盐酸盐及其治疗疼痛和代谢紊乱的用途
CN103957916A (zh) *	2011-09-30	2014-07-30	詹森药业有限公司	用于治疗代谢疾病和相关失调的单酰甘油脂肪酶抑制剂
MX350788B (es)	2012-01-06	2017-09-13	Abide Therapeutics Inc	Compuestos de carbamato y preparación y uso de los mismos.
CN102603485A (zh) *	2012-02-07	2012-07-25	北京颖新泰康国际贸易有限公司	制备2-甲基-3-苯基苯甲醇的方法
TWI562295B (en)	2012-07-31	2016-12-11	Mediatek Inc	Semiconductor package and method for fabricating base for semiconductor package
CA2890664A1 (en)	2012-11-08	2014-05-15	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014139144A1 (en)	2013-03-15	2014-09-18	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions
WO2014143659A1 (en)	2013-03-15	2014-09-18	Araxes Pharma Llc	Irreversible covalent inhibitors of the gtpase k-ras g12c
US9227978B2 (en)	2013-03-15	2016-01-05	Araxes Pharma Llc	Covalent inhibitors of Kras G12C
EP3401314B1 (en) *	2013-03-15	2023-11-08	Araxes Pharma LLC	Covalent inhibitors of kras g12c
US9655887B2 (en)	2013-05-23	2017-05-23	Bayer Pharma Aktiengesellschaft	Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
TWI659021B (zh)	2013-10-10	2019-05-11	亞瑞克西斯製藥公司	Ｋｒａｓｇ１２ｃ之抑制劑
JP6229056B2 (ja) *	2013-11-12	2017-11-08	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	神経変性疾患の処置用の神経新生薬としてのピリド［４，３−ｂ］ピラジン−２−カルボキサミド
EP3087067B1 (en)	2013-12-26	2018-10-24	Takeda Pharmaceutical Company Limited	4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
JO3556B1 (ar)	2014-09-18	2020-07-05	Araxes Pharma Llc	علاجات مدمجة لمعالجة السرطان
EP3197450A1 (en)	2014-09-22	2017-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of fibrosis
EP3197870B1 (en)	2014-09-25	2020-08-19	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10011600B2 (en)	2014-09-25	2018-07-03	Araxes Pharma Llc	Methods and compositions for inhibition of Ras
US10106556B2 (en)	2015-03-30	2018-10-23	Takeda Pharmaceutical Company Limited	Heterocyclic compound
EA201792214A1 (ru)	2015-04-10	2018-01-31	Араксис Фарма Ллк	Соединения замещенного хиназолина
CA2982360A1 (en)	2015-04-15	2016-10-20	Liansheng Li	Fused-tricyclic inhibitors of kras and methods of use thereof
MY186368A (en) *	2015-07-20	2021-07-16	Genzyme Corp	Colony stimulating factor-1 receptor (csf-1r) inhibitors
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
HK1249101A1 (zh)	2015-07-31	2018-10-26	辉瑞公司	作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
EP3356359B1 (en)	2015-09-28	2021-10-20	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10975071B2 (en)	2015-09-28	2021-04-13	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en)	2015-09-28	2020-12-29	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
EP3356351A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
US10689356B2 (en)	2015-09-28	2020-06-23	Araxes Pharma Llc	Inhibitors of KRAS G12C mutant proteins
WO2017058728A1 (en)	2015-09-28	2017-04-06	Araxes Pharma Llc	Inhibitors of kras g12c mutant proteins
EP3356354A1 (en)	2015-09-28	2018-08-08	Araxes Pharma LLC	Inhibitors of kras g12c mutant proteins
EP3364977A4 (en)	2015-10-19	2019-09-04	Araxes Pharma LLC	PROCESS FOR SCREENING INHIBITORS OF RAS
KR20180081596A (ko)	2015-11-16	2018-07-16	아락세스 파마 엘엘씨	치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en)	2015-12-09	2018-06-05	Araxes Pharma Llc	Methods for preparation of quinazoline derivatives
EP3407886A1 (en)	2016-01-27	2018-12-05	Universität Zürich	Use of gabaa receptor modulators for treatment of itch
US10463753B2 (en)	2016-02-19	2019-11-05	Lundbeck La Jolla Research Center, Inc.	Radiolabeled monoacylglycerol lipase occupancy probe
WO2017172979A1 (en)	2016-03-30	2017-10-05	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use
DK3436444T3 (da) *	2016-03-31	2020-07-27	Takeda Pharmaceuticals Co	Heterocyklisk forbindelse
WO2017170830A1 (ja)	2016-03-31	2017-10-05	武田薬品工業株式会社	複素環化合物
US10646488B2 (en)	2016-07-13	2020-05-12	Araxes Pharma Llc	Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh)	2016-09-29	2019-07-19	亚瑞克西斯制药公司	Kras g12c突变蛋白的抑制剂
WO2018068017A1 (en)	2016-10-07	2018-04-12	Araxes Pharma Llc	Heterocyclic compounds as inhibitors of ras and methods of use thereof
JOP20190106A1 (ar) *	2016-11-16	2019-05-09	Lundbeck La Jolla Research Center Inc	مثبطات أحادي أسيل جليسرول ليباز (magl)
JP2020506899A (ja)	2017-01-20	2020-03-05	ファイザー・インク	Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体
RU2726631C1 (ru)	2017-01-23	2020-07-15	Пфайзер Инк.	Гетероциклические спиросоединения в качестве ингибиторов magl
US11358959B2 (en)	2017-01-26	2022-06-14	Araxes Pharma Llc	Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en)	2017-01-26	2019-12-04	Araxes Pharma LLC	1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP7327802B2 (ja)	2017-01-26	2023-08-16	アラクセスファーマエルエルシー	縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
WO2018140514A1 (en)	2017-01-26	2018-08-02	Araxes Pharma Llc	1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11274093B2 (en)	2017-01-26	2022-03-15	Araxes Pharma Llc	Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11655217B2 (en)	2017-05-23	2023-05-23	H. Lundbeck A/S	Pyrazole MAGL inhibitors
US10927105B1 (en)	2017-05-23	2021-02-23	Lundbeck La Jolla Research Center, Inc.	Pyrazole MAGL inhibitors
EP3630747A1 (en)	2017-05-25	2020-04-08	Araxes Pharma LLC	Quinazoline derivatives as modulators of mutant kras, hras or nras
WO2018218071A1 (en)	2017-05-25	2018-11-29	Araxes Pharma Llc	Compounds and methods of use thereof for treatment of cancer
AU2018271990A1 (en)	2017-05-25	2019-12-12	Araxes Pharma Llc	Covalent inhibitors of KRAS
EP3689879B1 (en)	2017-09-29	2025-02-12	Takeda Pharmaceutical Company Limited	Heterocyclic compound
CN112135825A (zh)	2018-03-13	2020-12-25	夏尔人类遗传性治疗公司	血浆激肽释放酶抑制剂及其用途
EP3790551A4 (en)	2018-05-07	2022-03-09	Mirati Therapeutics, Inc.	Kras g12c inhibitors
PE20211385A1 (es)	2018-05-15	2021-07-27	Lundbeck La Jolla Research Center Inc	Inhibidores de magl
CA3107168A1 (en)	2018-08-01	2020-02-06	Araxes Pharma Llc	Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
ES3004338T3 (en)	2018-09-10	2025-03-12	Mirati Therapeutics Inc	Combination therapies
US12336995B2 (en)	2018-09-10	2025-06-24	Mirati Therapeutics, Inc.	Combination therapies
CA3111980A1 (en)	2018-09-10	2020-03-19	Mirati Therapeutics, Inc.	Combination therapies
WO2020055760A1 (en)	2018-09-10	2020-03-19	Mirati Therapeutics, Inc.	Combination therapies
CN109020890B (zh) *	2018-09-12	2022-02-08	南京大学	一类饱和脂肪环骈吡唑衍生物的制备及其应用
CA3118752A1 (en) *	2018-11-09	2020-05-14	Vivace Therapeutics, Inc.	Bicyclic compounds
JP2022509206A (ja) *	2018-11-28	2022-01-20	ハー・ルンドベック・アクチエゼルスカベット	Ｍａｇｌ阻害剤による疾病の治療方法
MX2021002804A (es)	2018-12-05	2021-07-15	Mirati Therapeutics Inc	Terapias de combinacion.
WO2020146613A1 (en)	2019-01-10	2020-07-16	Mirati Therapeutics, Inc.	Kras g12c inhibitors
US12304897B2 (en) *	2019-01-31	2025-05-20	Kyorin Pharmaceutical Co., Ltd.	15-PGDH inhibitors
WO2020179859A1 (ja)	2019-03-06	2020-09-10	第一三共株式会社	ピロロピラゾール誘導体
AU2020257207A1 (en)	2019-04-16	2021-11-25	Vivace Therapeutics, Inc.	Bicyclic compounds
BR112022003543A2 (pt)	2019-08-29	2022-05-24	Array Biopharma Inc	Inibidores de kras g12
WO2021055589A1 (en)	2019-09-18	2021-03-25	Shire Human Genetic Therapies, Inc.	Heteroaryl plasma kallikrein inhibitors
PL4031547T3 (pl)	2019-09-18	2024-10-07	Takeda Pharmaceutical Company Limited	Inhibitory kalikreiny osoczowej i ich zastosowania
WO2021061749A1 (en)	2019-09-24	2021-04-01	Mirati Therapeutics, Inc.	Combination therapies
KR20220075386A (ko)	2019-09-30	2022-06-08	얀센 파마슈티카 엔.브이.	방사성 표지된 mgl pet 리간드
US11702418B2 (en)	2019-12-20	2023-07-18	Mirati Therapeutics, Inc.	SOS1 inhibitors
IL294881A (en) *	2020-01-23	2022-09-01	Myoforte Therapeutics Inc	pgdh inhibitors and methods of preparation and use
EP3875452A1 (en) *	2020-03-04	2021-09-08	Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis	Monoacylglycerol lipase inhibitors
EP4126825A1 (en) *	2020-03-26	2023-02-08	Janssen Pharmaceutica NV	Aminocyclobutanes as monoacylglycerol lipase modulators
CA3190944A1 (en)	2020-09-11	2022-03-17	Mirati Therapeutics, Inc.	Crystalline forms of a kras g12c inhibitor
EP4228650A4 (en) *	2020-10-15	2024-12-18	Myoforte Therapeutics Inc.	INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
CA3198885A1 (en)	2020-12-15	2022-06-23	Xiaolun Wang	Azaquinazoline pan-kras inhibitors
WO2022133038A1 (en)	2020-12-16	2022-06-23	Mirati Therapeutics, Inc.	Tetrahydropyridopyrimidine pan-kras inhibitors
JP2024500919A (ja)	2020-12-23	2024-01-10	ジェンザイム・コーポレーション	重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
KR102682408B1 (ko) *	2021-05-12	2024-07-05	에이치케이이노엔 주식회사	신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
WO2023009618A1 (en) *	2021-07-28	2023-02-02	Epirium Bio, Inc.	Bicyclic pgdh inhibitors and methods of making and using
WO2023130023A1 (en)	2021-12-29	2023-07-06	Psy Therapeutics, Inc.	Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9600235D0 (en) *	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
EP0968200A1 (en)	1997-02-24	2000-01-05	ZymoGenetics, Inc.	Calcitonin mimetics
AU1089599A (en)	1997-10-15	1999-05-03	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
AU3565999A (en)	1999-04-16	2000-11-02	Coelacanth Chemical Corporation	Synthesis of azetidine derivatives
US6566356B2 (en)	2000-03-03	2003-05-20	Aventis Pharma S.A.	Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
AR033517A1 (es)	2000-04-08	2003-12-26	Astrazeneca Ab	Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
FR2829028B1 (fr)	2001-08-29	2004-12-17	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
AR037364A1 (es) *	2001-11-16	2004-11-03	Schering Corp	Azetidinil diaminas utiles como ligandos del receptor de nociceptina orl-1
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
TW200410688A (en) *	2002-06-26	2004-07-01	Ono Pharmaceutical Co	Therapeutics for diseases from vasoconstriction or vasodilatation
US7435736B2 (en) *	2002-12-23	2008-10-14	Janssen Pharmaceutica, N.V.	Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
FR2854633B1 (fr) *	2003-05-07	2005-06-24	Sanofi Synthelabo	Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique
DE602004013772D1 (de) *	2003-06-10	2008-06-26	Janssen Pharmaceutica Nv	Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen
EP1702916A1 (en)	2005-03-18	2006-09-20	Santhera Pharmaceuticals (Schweiz) GmbH	DPP-IV inhibitors
MX2007015606A (es) *	2005-06-23	2008-02-25	Astrazeneca Ab	Nuevos derivados de azetidina como antagonistas del receptor de neuroquinina para el tratamiento de enfermedades gastrointestinales.
US7879880B2 (en)	2005-12-21	2011-02-01	Schering Corporation	Substituted aniline derivatives useful as histamine H3 antagonists
DE102006016023A1 (de) *	2006-04-05	2007-10-11	Basf Ag	Funktionale Expression von Triacylglycerol-Lipasen
TWI403508B (zh)	2006-08-26	2013-08-01	Abbott Gmbh & Co Kg	經取代苯并咪唑酮衍生物、包含其之醫藥品及其用途
FR2915199B1 (fr) *	2007-04-18	2010-01-22	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915197B1 (fr) *	2007-04-18	2009-06-12	Sanofi Aventis Sa	Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2915198B1 (fr)	2007-04-18	2009-12-18	Sanofi Aventis	Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2009117444A1 (en)	2008-03-17	2009-09-24	Northeastern University	Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
CA2722449C (en)	2008-04-25	2016-11-08	Carsten Schubert	Crystal structure of monoacylglycerol lipase (mgll)
EP2180048B1 (en)	2008-10-09	2014-12-17	Janssen Pharmaceutica N.V.	Alternative crystal form of monoacylglycerol lipase (MGLL)
US8435977B2 (en)	2009-04-22	2013-05-07	Janssen Pharmaceutica, Nv	Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
PT2421852E (pt)	2009-04-22	2014-07-31	Janssen Pharmaceutica Nv	Amidas de piperazinil azetidinil heteroaromáticas e aromáticas como inibidoras da lipase de monoacilglicerol
BRPI1013545A2 (pt) *	2009-04-22	2019-09-24	Janssen Phamaceutica N V	azetidinil diamidas como inibidores de monoacilglicerol lipase
DE102012109699A1 (de) *	2012-10-11	2014-04-17	Pavel Abdulkin	Verfahren zum Bereitstellen einer Gold-Nano-Hülle um kleine, magnetische Partikel im Submikrometerbereich und so erhaltene Partikel

2010
- 2010-04-22 BR BRPI1013545A patent/BRPI1013545A2/pt not_active IP Right Cessation
- 2010-04-22 CN CN2010800287463A patent/CN102803210A/zh active Pending
- 2010-04-22 CA CA2759713A patent/CA2759713A1/en not_active Abandoned
- 2010-04-22 AR ARP100101341A patent/AR076380A1/es not_active Application Discontinuation
- 2010-04-22 TW TW099112752A patent/TW201105665A/zh unknown
- 2010-04-22 RS RS20140136A patent/RS53235B/sr unknown
- 2010-04-22 US US12/765,018 patent/US8426401B2/en active Active
- 2010-04-22 JP JP2012507377A patent/JP2012524800A/ja not_active Withdrawn
- 2010-04-22 CA CA2759621A patent/CA2759621C/en not_active Expired - Fee Related
- 2010-04-22 WO PCT/US2010/032089 patent/WO2010124114A1/en not_active Ceased
- 2010-04-22 KR KR1020117027313A patent/KR20120034615A/ko not_active Withdrawn
- 2010-04-22 RU RU2011147200/04A patent/RU2011147200A/ru not_active Application Discontinuation
- 2010-04-22 RU RU2011147230/04A patent/RU2011147230A/ru not_active Application Discontinuation
- 2010-04-22 AU AU2010239188A patent/AU2010239188B2/en not_active Ceased
- 2010-04-22 BR BRPI1014284A patent/BRPI1014284A2/pt not_active IP Right Cessation
- 2010-04-22 RU RU2011147236/04A patent/RU2011147236A/ru not_active Application Discontinuation
- 2010-04-22 CN CN2010800287586A patent/CN102459255A/zh active Pending
- 2010-04-22 PT PT107162059T patent/PT2421825E/pt unknown
- 2010-04-22 JP JP2012507389A patent/JP2012524805A/ja not_active Withdrawn
- 2010-04-22 EP EP10716205.9A patent/EP2421825B9/en active Active
- 2010-04-22 EP EP10716672A patent/EP2421856A1/en not_active Withdrawn
- 2010-04-22 JP JP2012507378A patent/JP5649644B2/ja not_active Expired - Fee Related
- 2010-04-22 AU AU2010238743A patent/AU2010238743A1/en not_active Abandoned
- 2010-04-22 KR KR1020117027324A patent/KR20120034616A/ko not_active Withdrawn
- 2010-04-22 WO PCT/US2010/032045 patent/WO2010124082A1/en not_active Ceased
- 2010-04-22 RU RU2011147207/04A patent/RU2011147207A/ru not_active Application Discontinuation
- 2010-04-22 KR KR1020117027654A patent/KR101705697B1/ko not_active Expired - Fee Related
- 2010-04-22 WO PCT/US2010/032049 patent/WO2010124086A1/en not_active Ceased
- 2010-04-22 AU AU2010239204A patent/AU2010239204A1/en not_active Abandoned
- 2010-04-22 US US12/765,179 patent/US8450303B2/en active Active
- 2010-04-22 CN CN201080028726.6A patent/CN102459166B/zh not_active Expired - Fee Related
- 2010-04-22 WO PCT/US2010/032092 patent/WO2010124116A1/en not_active Ceased
- 2010-04-22 BR BRPI1014885A patent/BRPI1014885A8/pt not_active Application Discontinuation
- 2010-04-22 KR KR1020117027713A patent/KR20120034623A/ko not_active Withdrawn
- 2010-04-22 JP JP2012507392A patent/JP2012524807A/ja not_active Withdrawn
- 2010-04-22 CN CN201080028749.7A patent/CN102459167B/zh not_active Expired - Fee Related
- 2010-04-22 US US12/765,048 patent/US8445477B2/en active Active
- 2010-04-22 CN CN2010800287603A patent/CN102548982A/zh active Pending
- 2010-04-22 HR HRP20140295AT patent/HRP20140295T1/hr unknown
- 2010-04-22 EP EP10715460A patent/EP2421824A1/en not_active Withdrawn
- 2010-04-22 AR ARP100101340A patent/AR076379A1/es not_active Application Discontinuation
- 2010-04-22 BR BRPI1014281A patent/BRPI1014281A2/pt not_active IP Right Cessation
- 2010-04-22 BR BRPI1013540-5A patent/BRPI1013540A2/pt not_active IP Right Cessation
- 2010-04-22 EP EP10715456A patent/EP2421860A1/en not_active Withdrawn
- 2010-04-22 TW TW099112749A patent/TWI465446B/zh not_active IP Right Cessation
- 2010-04-22 AR ARP100101335A patent/AR076374A1/es not_active Application Discontinuation
- 2010-04-22 JP JP2012507382A patent/JP2012524802A/ja not_active Withdrawn
- 2010-04-22 EP EP10715457.7A patent/EP2421823B1/en active Active
- 2010-04-22 WO PCT/US2010/032082 patent/WO2010124108A1/en not_active Ceased
- 2010-04-22 EP EP10717365A patent/EP2421847A1/en not_active Withdrawn
- 2010-04-22 CA CA2759505A patent/CA2759505A1/en not_active Abandoned
- 2010-04-22 CN CN2010800287478A patent/CN102459230A/zh active Pending
- 2010-04-22 CA CA2759547A patent/CA2759547A1/en not_active Abandoned
- 2010-04-22 TW TW099112751A patent/TW201116280A/zh unknown
- 2010-04-22 TW TW099112746A patent/TW201105654A/zh unknown
- 2010-04-22 US US12/765,103 patent/US8455476B2/en active Active
- 2010-04-22 RU RU2011147181/04A patent/RU2011147181A/ru not_active Application Discontinuation
- 2010-04-22 RU RU2011147185/04A patent/RU2011147185A/ru not_active Application Discontinuation
- 2010-04-22 AR ARP100101342A patent/AR076381A1/es not_active Application Discontinuation
- 2010-04-22 CA CA2759604A patent/CA2759604A1/en not_active Abandoned
- 2010-04-22 JP JP2012507390A patent/JP2012524806A/ja not_active Withdrawn
- 2010-04-22 AU AU2010238736A patent/AU2010238736A1/en not_active Abandoned
- 2010-04-22 KR KR1020117027340A patent/KR20120035146A/ko not_active Withdrawn
- 2010-04-22 US US12/765,076 patent/US8367653B2/en active Active
- 2010-04-22 CA CA2759697A patent/CA2759697A1/en not_active Abandoned
- 2010-04-22 PL PL10716205T patent/PL2421825T3/pl unknown
- 2010-04-22 BR BRPI1013538A patent/BRPI1013538A2/pt not_active IP Right Cessation
- 2010-04-22 EP EP10716203A patent/EP2421851A1/en not_active Withdrawn
- 2010-04-22 WO PCT/US2010/032068 patent/WO2010124102A1/en not_active Ceased
- 2010-04-22 JP JP2012507388A patent/JP2012524804A/ja not_active Withdrawn
- 2010-04-22 AU AU2010239184A patent/AU2010239184A1/en not_active Abandoned
- 2010-04-22 CA CA2759501A patent/CA2759501A1/en not_active Abandoned
- 2010-04-22 US US12/765,487 patent/US8362001B2/en active Active
- 2010-04-22 AR ARP100101337A patent/AR076376A1/es unknown
- 2010-04-22 WO PCT/US2010/032086 patent/WO2010124112A1/en not_active Ceased
- 2010-04-22 WO PCT/US2010/032095 patent/WO2010124119A1/en not_active Ceased
- 2010-04-22 AR ARP100101338A patent/AR076377A1/es not_active Application Discontinuation
- 2010-04-22 JP JP2012507387A patent/JP5733840B2/ja not_active Expired - Fee Related
- 2010-04-22 TW TW099112750A patent/TW201103931A/zh unknown
- 2010-04-22 CN CN2010800287590A patent/CN102459228A/zh active Pending
- 2010-04-22 AU AU2010238738A patent/AU2010238738A1/en not_active Abandoned
- 2010-04-22 TW TW099112747A patent/TWI483940B/zh not_active IP Right Cessation
- 2010-04-22 BR BRPI1015238A patent/BRPI1015238A2/pt not_active IP Right Cessation
- 2010-04-22 ES ES10716205.9T patent/ES2455744T3/es active Active
- 2010-04-22 AR ARP100101339A patent/AR076378A1/es unknown
- 2010-04-22 ES ES10715457.7T patent/ES2538326T3/es active Active
- 2010-04-22 KR KR1020117027691A patent/KR101705049B1/ko not_active Expired - Fee Related
- 2010-04-22 RU RU2011147206/04A patent/RU2569298C2/ru not_active IP Right Cessation
- 2010-04-22 TW TW099112753A patent/TW201103932A/zh unknown
- 2010-04-22 TW TW099112748A patent/TW201105655A/zh unknown
- 2010-04-22 US US12/765,254 patent/US8399454B2/en active Active
- 2010-04-22 RU RU2011147233/04A patent/RU2549547C2/ru not_active IP Right Cessation
- 2010-04-22 BR BRPI1014876A patent/BRPI1014876A2/pt not_active IP Right Cessation
- 2010-04-22 AU AU2010238732A patent/AU2010238732B2/en not_active Ceased
- 2010-04-22 CN CN2010800288396A patent/CN102459240A/zh active Pending
- 2010-04-22 CA CA2759614A patent/CA2759614C/en not_active Expired - Fee Related
- 2010-04-22 AR ARP100101343A patent/AR076382A1/es not_active Application Discontinuation
- 2010-04-22 KR KR1020117027341A patent/KR20110137831A/ko not_active Withdrawn
- 2010-04-22 EP EP10715461A patent/EP2421848A1/en not_active Withdrawn
- 2010-04-22 KR KR1020117027334A patent/KR20120034617A/ko not_active Withdrawn
- 2010-04-22 US US12/765,420 patent/US8362000B2/en active Active
- 2010-04-22 AU AU2010238740A patent/AU2010238740A1/en not_active Abandoned
- 2010-04-22 DK DK10716205.9T patent/DK2421825T3/da active
- 2010-04-22 SI SI201030535T patent/SI2421825T1/sl unknown
2011
- 2011-10-23 IL IL215787A patent/IL215787A0/en unknown
- 2011-10-23 IL IL215775A patent/IL215775A0/en unknown
- 2011-10-23 IL IL215773A patent/IL215773A/en not_active IP Right Cessation
- 2011-10-23 IL IL215780A patent/IL215780A/en not_active IP Right Cessation
- 2011-10-23 IL IL215798A patent/IL215798A0/en unknown
- 2011-10-23 IL IL215785A patent/IL215785A0/en unknown
- 2011-10-23 IL IL215786A patent/IL215786A0/en unknown
- 2011-10-23 IL IL215781A patent/IL215781A0/en unknown
2012
- 2012-12-17 US US13/716,705 patent/US8604017B2/en not_active Expired - Fee Related
- 2012-12-18 US US13/718,257 patent/US8623858B2/en not_active Expired - Fee Related
- 2012-12-18 US US13/718,056 patent/US8741887B2/en active Active
2013
- 2013-01-25 US US13/749,846 patent/US8722658B2/en active Active
- 2013-03-18 US US13/845,982 patent/US8697683B2/en active Active
- 2013-04-22 US US13/867,372 patent/US8962607B2/en active Active
- 2013-04-29 US US13/872,427 patent/US8697684B2/en active Active
- 2013-05-01 US US13/874,835 patent/US8691805B2/en active Active
2014
- 2014-03-20 SM SM201400034T patent/SMT201400034B/xx unknown
2016
- 2016-03-03 AU AU2016201405A patent/AU2016201405A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2421825A1 (en)	2012-02-29
US8604017B2 (en)	2013-12-10
SI2421825T1 (sl)	2014-04-30
BRPI1014281A2 (pt)	2019-09-24
CA2759621A1 (en)	2010-10-28
EP2421824A1 (en)	2012-02-29
US20100324011A1 (en)	2010-12-23
RU2011147181A (ru)	2013-05-27
IL215785A0 (en)	2012-01-31
EP2421860A1 (en)	2012-02-29
PL2421825T3 (pl)	2014-06-30
CN102459255A (zh)	2012-05-16
BRPI1014876A2 (pt)	2016-04-12
JP2012524807A (ja)	2012-10-18
IL215780A0 (en)	2012-01-31
AU2010238732B2 (en)	2015-06-11
US8362000B2 (en)	2013-01-29
EP2421848A1 (en)	2012-02-29
KR20120034617A (ko)	2012-04-12
AR076377A1 (es)	2011-06-08
CN102459230A (zh)	2012-05-16
IL215781A0 (en)	2012-01-31
AR076380A1 (es)	2011-06-08
WO2010124102A1 (en)	2010-10-28
US20130244997A1 (en)	2013-09-19
IL215773A (en)	2015-05-31
RS53235B (sr)	2014-08-29
US20140243305A1 (en)	2014-08-28
AR076374A1 (es)	2011-06-08
AR076381A1 (es)	2011-06-08
CN102459167B (zh)	2015-04-01
BRPI1014284A2 (pt)	2017-10-10
RU2011147233A (ru)	2013-05-27
KR20110137834A (ko)	2011-12-23
CA2759697A1 (en)	2010-10-28
EP2421825B9 (en)	2014-08-20
US8691805B2 (en)	2014-04-08
AU2010239188A1 (en)	2011-11-10
JP2012524804A (ja)	2012-10-18
TWI465446B (zh)	2014-12-21
TW201105655A (en)	2011-02-16
BRPI1015238A2 (pt)	2019-09-24
CN102548982A (zh)	2012-07-04
US8962607B2 (en)	2015-02-24
US8426401B2 (en)	2013-04-23
BRPI1014885A8 (pt)	2018-04-10
US8362001B2 (en)	2013-01-29
KR20110137831A (ko)	2011-12-23
EP2421851A1 (en)	2012-02-29
CN102459240A (zh)	2012-05-16
WO2010124116A1 (en)	2010-10-28
ES2538326T3 (es)	2015-06-19
AR076379A1 (es)	2011-06-08
RU2011147200A (ru)	2013-05-27
WO2010124114A1 (en)	2010-10-28
CA2759621C (en)	2017-09-26
EP2421823B1 (en)	2015-01-14
KR20120034616A (ko)	2012-04-12
BRPI1014885A2 (pt)	2016-04-19
CN102459166B (zh)	2015-03-25
WO2010124108A1 (en)	2010-10-28
US8722658B2 (en)	2014-05-13
AR076376A1 (es)	2011-06-08
DK2421825T3 (da)	2014-02-03
EP2421856A1 (en)	2012-02-29
TW201105654A (en)	2011-02-16
AU2010238732A1 (en)	2011-11-10
CN102459166A (zh)	2012-05-16
ES2455744T3 (es)	2014-04-16
RU2011147206A (ru)	2013-05-27
CA2759505A1 (en)	2010-10-28
TW201105665A (en)	2011-02-16
JP2012524803A (ja)	2012-10-18
TW201116280A (en)	2011-05-16
TW201103930A (en)	2011-02-01
RU2011147230A (ru)	2013-05-27
US20100331299A1 (en)	2010-12-30
EP2421847A1 (en)	2012-02-29
US20100324014A1 (en)	2010-12-23
IL215798A0 (en)	2012-01-31
WO2010124112A1 (en)	2010-10-28
HK1170221A1 (en)	2013-02-22
AR076378A1 (es)	2011-06-08
JP2012524801A (ja)	2012-10-18
US20130137674A1 (en)	2013-05-30
US20130123232A1 (en)	2013-05-16
WO2010124082A1 (en)	2010-10-28
IL215787A0 (en)	2012-01-31
AU2010238736A1 (en)	2011-11-10
KR20120034615A (ko)	2012-04-12
CA2759614A1 (en)	2010-10-28
US8450303B2 (en)	2013-05-28
RU2011147207A (ru)	2013-05-27
WO2010124119A1 (en)	2010-10-28
CA2759604A1 (en)	2010-10-28
US20100324012A1 (en)	2010-12-23
US20100331300A1 (en)	2010-12-30
US8697684B2 (en)	2014-04-15
PT2421825E (pt)	2014-03-13
US8741887B2 (en)	2014-06-03
RU2569298C2 (ru)	2015-11-20
JP5733840B2 (ja)	2015-06-10
US8697683B2 (en)	2014-04-15
US20110015170A1 (en)	2011-01-20
AU2016201405A1 (en)	2016-03-24
JP2012524802A (ja)	2012-10-18
IL215773A0 (en)	2012-01-31
CA2759547A1 (en)	2010-10-28
CA2759614C (en)	2017-09-19
KR20120034622A (ko)	2012-04-12
US20130217669A1 (en)	2013-08-22
US8367653B2 (en)	2013-02-05
AU2010239204A1 (en)	2011-11-10
AU2010238740A1 (en)	2011-11-10
CN102459228A (zh)	2012-05-16
TW201103931A (en)	2011-02-01
CA2759713A1 (en)	2010-10-28
TW201103918A (en)	2011-02-01
RU2011147185A (ru)	2013-05-27
AU2010238743A1 (en)	2011-11-10
TW201103932A (en)	2011-02-01
JP5649644B2 (ja)	2015-01-07
JP2012524806A (ja)	2012-10-18
JP2012524805A (ja)	2012-10-18
US8445477B2 (en)	2013-05-21
KR101705049B1 (ko)	2017-02-09
EP2421825B1 (en)	2014-01-01
BRPI1013540A2 (pt)	2020-11-17
US20130102585A1 (en)	2013-04-25
US20100324013A1 (en)	2010-12-23
US20130123233A1 (en)	2013-05-16
TWI483940B (zh)	2015-05-11
RU2549547C2 (ru)	2015-04-27
AU2010239188B2 (en)	2016-03-31
HRP20140295T1 (hr)	2014-04-25
SMT201400034B (it)	2014-05-07
RU2011147236A (ru)	2013-05-27
US8623858B2 (en)	2014-01-07
AU2010238738A1 (en)	2011-11-10
IL215786A0 (en)	2012-01-31
US20130237517A1 (en)	2013-09-12
US8399454B2 (en)	2013-03-19
KR20120035146A (ko)	2012-04-13
CA2759501A1 (en)	2010-10-28
KR20120034623A (ko)	2012-04-12
WO2010124086A1 (en)	2010-10-28
US20110015171A1 (en)	2011-01-20
HK1170228A1 (en)	2013-02-22
AR076382A1 (es)	2011-06-08
BRPI1013545A2 (pt)	2019-09-24
EP2421823A1 (en)	2012-02-29
IL215775A0 (en)	2012-01-31
CN102803210A (zh)	2012-11-28
KR101705697B1 (ko)	2017-02-10
JP2012524800A (ja)	2012-10-18
IL215780A (en)	2015-05-31
US8455476B2 (en)	2013-06-04
AU2010239184A1 (en)	2011-11-10
CN102459167A (zh)	2012-05-16

Publication	Publication Date	Title
BRPI1013545A2 (pt)	2019-09-24	azetidinil diamidas como inibidores de monoacilglicerol lipase
BR112013009858A2 (pt)	2016-07-26	diamidas de piperidin-4-il-azetidina como inibidores de monoacilglicerol lipase
BR112013009828A2 (pt)	2016-07-26	diamidas de amino-pirrolidina-azetidina como inibidores de monoacilglicerol lipase
EP2346734A4 (en)	2013-01-02	ACTIVE WINGLET
PT2225988E (pt)	2014-02-25	Suporte de distribuidor
BR112012003787A2 (pt)	2017-07-04	variantes de glicoamilase
EP2475761A4 (en)	2015-04-22	PHOTO BIOREACTOR
UY33155A (es)	2011-07-29	Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
BRPI1014888A2 (pt)	2019-09-24	piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase
DK3473711T3 (da)	2021-01-04	Amylasepolypeptider
EP2516615A4 (en)	2016-05-25	IMPROVED BIOREACTORS
BRPI1008744A2 (pt)	2016-03-15	hidrotratamento de caboidratos
BRPI1014874A2 (pt)	2016-04-12	piperazinil azetidinil amidas heteroaromáticas e aromáticas como inibidores de monoacilglicerol lipase
EP2601279A4 (en)	2014-03-05	SUPERTORREFICATION FROM BIOMASS TO BIO COAL
BR112013015450A2 (pt)	2017-09-26	disposição de injetor
EP2531219A4 (en)	2015-01-14	Carrier composition
DK2606116T3 (da)	2020-08-03	Bioreaktorsystem
BRPI1009018A2 (pt)	2015-12-01	fotobiorreator
DK2516435T3 (da)	2014-10-13	Inhibitorer af AKT-aktivitet
BRPI1015272A2 (pt)	2015-08-25	Fermentação
DE102009039391A8 (de)	2011-06-01	Abstrichtupfersystem
UY33136A (es)	2011-07-29	Tropinonabencilaminas como inhibidores de la beta-triptasa
EP2493665A4 (en)	2014-05-07	MULTISELECTIVE MICROMANIPULATOR
ES1073954Y (es)	2011-06-09	Columna de cultivo
FI20105700A0 (fi)	2010-06-17	Entsyymielektrodi

Legal Events

Date	Code	Title	Description
2019-10-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2020-01-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.